SavedAdd your journal

Journals / Journal of Istanbul Veterinary Sciences / 2024 / Cilt: 8 Sayı: 3

Hematological and blood biochemical differences in dogs with mammary dysplasia/ hyperplasia, bening or malignant mammary tumors

Orkun Hacıoğlu(İstanbul Üniversitesi- Cerrahpaşa)0000-0003-4307-4897
Rabia Buse Aksu(İstanbul Üniversitesi- Cerrahpaşa)0000-0002-2572-4289
Sinem Yaren Akgül(İstanbul Üniversitesi- Cerrahpaşa)0009-0005-3777-2738
Tuğba Seval Fatma Toydemir Karabulut(İstanbul Üniversitesi- Cerrahpaşa)0000-0001-6416-8337
Pages
273–281
Publication Date
2024-12-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

While our study revealed some potential associations between hematologic parameters and histopathological tumor types, further studies with a larger and more diverse canine population are needed before these parameters can be reliably used as prognostic markers in female dogs with mammary masses.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Mammary tumors are the most common neoplasms in female dogs.
📊
Key Findings & Data:For this, hematocrit (HCT), blood biochemistry, and some clinical and histopathological findings of female dogs with mammary gland masses that had undergone mastectomy (n = 100) were included in our study.
💡
Conclusion & Impact:While our study revealed some potential associations between hematologic parameters and histopathological tumor types, further studies with a larger and more diverse canine population are needed before these parameters can be reliably used as prognostic markers in female dogs with mammary masses.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Canine · Mammary Tumor · CBC

Abstract

Mammary tumors are the most common neoplasms in female dogs. There are many factors involved in the development of mammary tumors. Recently, there is an increasing need for cost-effective prognostic markers derived from hematological parameters in dogs and cats with cancer. Our study was designed as a retrospective study to determine the significance of hematologic parameters in female dogs bearing with mammary tumors. For this, hematocrit (HCT), blood biochemistry, and some clinical and histopathological findings of female dogs with mammary gland masses that had undergone mastectomy (n = 100) were included in our study. Mammary masses in female dogs are divided into five histopathological groups: Group 1 (malignant epithelial tumors), Group 2 (malignant mesenchymal tumors), Group 3 (malignant mixed tumors), Group 4 (benign tumors) and Group 5 (hyperplasia/dysplasia). The following hematologic parameters were evaluated: leukocytes (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), erythrocytes (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), platelets (PLT),mean platelet volume (MPV), and neutrophil to lymphocyte ratio (NLR). Biochemical analysis included blood urea nitrogen (BUN), creatinine (CRE), alanine aminotransferase (ALT), glucose (GLU), total protein (TP), alkaline phosphatase (ALP), and albumin/globulin ratio (AGR). Comparisons were made between the groups according to histopathological tumor types. The most common histopathological type after mastectomy is malignant epithelial tumors (72%). For TP, a difference was found between G1 and G5 (p 0.05). For MON, a difference was found between G1 and G5, between G2 and G5, between G3 and G5, between G1 and G4, between G3 and G4 (p 0.05). For PLT, a difference was found between G2-G3 and G3-G4 (p 0.05). Although NLR was different between the groups and gets higher values with malignancy no statistical significance was found between the groups (p 0.05). While our study revealed some potential associations between hematologic parameters and histopathological tumor types, further studies with a larger and more diverse canine population are needed before these parameters can be reliably used as prognostic markers in female dogs with mammary masses.

Özet

Mammary tumors are the most common neoplasms in female dogs. There are many factors involved in the development of mammary tumors. Recently, there is an increasing need for cost-effective prognostic markers derived from hematological parameters in dogs and cats with cancer. Our study was designed as a retrospective study to determine the significance of hematologic parameters in female dogs bearing with mammary tumors. For this, hematocrit (HCT), blood biochemistry, and some clinical and histopathological findings of female dogs with mammary gland masses that had undergone mastectomy (n = 100) were included in our study. Mammary masses in female dogs are divided into five histopathological groups: Group 1 (malignant epithelial tumors), Group 2 (malignant mesenchymal tumors), Group 3 (malignant mixed tumors), Group 4 (benign tumors) and Group 5 (hyperplasia/dysplasia). The following hematologic parameters were evaluated: leukocytes (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), erythrocytes (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), platelets (PLT),mean platelet volume (MPV), and neutrophil to lymphocyte ratio (NLR). Biochemical analysis included blood urea nitrogen (BUN), creatinine (CRE), alanine aminotransferase (ALT), glucose (GLU), total protein (TP), alkaline phosphatase (ALP), and albumin/globulin ratio (AGR). Comparisons were made between the groups according to histopathological tumor types. The most common histopathological type after mastectomy is malignant epithelial tumors (72%). For TP, a difference was found between G1 and G5 (p 0.05). For MON, a difference was found between G1 and G5, between G2 and G5, between G3 and G5, between G1 and G4, between G3 and G4 (p 0.05). For PLT, a difference was found between G2-G3 and G3-G4 (p 0.05). Although NLR was different between the groups and gets higher values with malignancy no statistical significance was found between the groups (p 0.05). While our study revealed some potential associations between hematologic parameters and histopathological tumor types, further studies with a larger and more diverse canine population are needed before these parameters can be reliably used as prognostic markers in female dogs with mammary masses.

🔖

Cite This Article

Hacıoğlu, O., Aksu, R. B., Akgül, S. Y., Karabulut, T. S. F. T., *, O. H. (2024). Hematological and blood biochemical differences in dogs with mammary dysplasia/ hyperplasia, bening or malignant mammary tumors. Journal of Istanbul Veterinary Sciences, Cilt: 8 Sayı: 3, 273–281. https://doi.org/10.30704/http-www-jivs-net.1475777

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. Andreasen, E. B., Tranholm, M., Wiinberg, B., Markussen, B., & Kristensen, A. (2012). Haemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression. Acta Veterinaria Scandinavica, 54(1), 3.
  2. Ariyarathna, H., Thomson, N. A., Aberdein, D., Perrott, M. R., & Munday, J. S. (2020). Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours. Veterinary Immunology and Immunopathology, 230, 110142
  3. Divsalar, B., Heydari, P., Habibollah, G., & Tamaddon, G. (2021). Hematological Parameters Changes in Patients with Breast Cancer. Clinical Laboratory, 67, 1832-1840.
  4. Egenvall, A., Bonnett, N. B., Ohagen, P., Olson, P., Hedhammar, A., & Euler, H. V. (2005). Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. Preventive Veterinary Medicine, 69, 109-127.
  5. Estrela-Lima, A., Araújo, S. M., Costa-Neto, J. M., Teixeira- Carvalho, A., Barrouin- Melo, S. M., Cardoso, S. V., Martins- Filho, O. A., Serakides, R., & Cassali, G. D. (2010). Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer, 10,256
  6. Gangwar, K., Yadav, B. K., Srivastav, A., Negi, A., Suresh, C. P., Pandey, H., Gangwar, N. K., N Prabhu, S., & Singh, R., (2024). Epidemiological, cytological, and haemato-serological analysis of canine mammary gland tumours. International Journal of Advanced Biochemistry Research, 8(2), 127-133.
  7. Goldschmidt, M., Peňa, L., Rasotto, R., & Zappulli, V. (2011). Classification and Grading of Canine Mammary Tumors, Veterinary Pathology, 48(1), 117-131.
  8. Hasan, M. H. S., Zaghlol, N. F., El-Shamy, S. A., & Latteef, D. K. (2015). Hematologıcal and bıochemıcal abnormalıtıes of canıne mammary gland tumors correlated to theır hıstopathologıcal types and serum bıomarkers. Assiut Veterinary Medical Journal, 61,145.
  9. Jee, S. H., Ohrr, H., Sull, J. W., Yun J. E., Ji, M., & Samet, J. M. (2005). Fasting Serum Glucose Level and Cancer Risk in Korean Men and Women. JAMA, 293(2), 194-202.
  10. Jurasz P., Alonso‐Escolano, D., & Radomski, M. W., (2004). Platelet–Cancer Interactions: Mechanisms and Pharmacology of Tumour Cell‐Induced Platelet Aggregation. British Journal of Pharmacology, 143(7), 819-826.
  11. Kırşan, İ., Canooğlu, E. (2016). Köpek ve kedilerde meme hastalıkları, In M. Kaymaz, M. Fındık, A. Rişvanlı, A. Köker (Ed). Evcil hayvanlarda meme hastalıkları (pp 317-348). Malatya, Türkiye: Medipres.
  12. Lallo, M. A., Ferraias, T. M., Stravino, A., Rodriguez, J. F. M., & Zucare, R. L. C. (2016). Hematologic abnormalities in dogs bearing mammary tumors. Revista Brasileira de Ciência Veterinária, 23(1/2), 03-08.
  13. Marquardt, C. (2003). Untersuchungen zur präoperativen Dignität serfassung kaniner mamatumoren mittels ultraschall und nadelbiopsie. Ph.D. Thesis, Justus Liebig University Giessen, Hesse, Germany.
  14. Moe, L. (2001). Population-based incidence of mammary tumours in some dog breeds. Journal of Reproduction and Fertility, 57, 439–443.
  15. Namagerdi, A. A., d’Angelo, D., Ciani, F., Lannuzzi, C. A., Napolitano, F., Avallone, L., Laurentiis, M. D., & Giordano, A. (2020). Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors Fromm Light Microscopy to Molecular Pathology. Frontiers in Oncology, 10, 563779.
  16. Nandhini, S., Madheswaran, R., Balasubramaniam, G. A., & Ramya, K., (2022). Clinico- pathological investigation of inflammatory mammary carcinomas in bitches. Indian Journal of Veterinary Pathology, 46(4), 277-282.
  17. Oliveira, M.R., Carneiro, R.A., Nunes, F.C., Teixeira, S.V., Vieira, T.C., & Lavalle, G.E. (2022). Hematological and biochemical alterations in female dogs with mammary cancer and inflammatory carcinoma. Arquivo Brasileiro de Medicina Veterinária e Zootecnia, 74(3), 428-436.
  18. Petrucci, G. N., Lobo, L., Queiroga F., Martins, J., Prada, J., Pires, I., & Henriques, J. (2021). Neutrophil-to-lymphocyte ratio is an independent prognostic marker for feline mammary carcinomas. Veterinary and Comparative Oncology, 19(3), 482-491.
  19. Satilmis, F., Alan, B. S., Altunok, V., Kivrak, M. B., Demirsöz, M., Alkan, H., & Aydin, İ. (2022). The effect of size and clinical staging of mammary tumors on blood parameters in bitches. Acta Scientiae Veterinariae, 50,1886. Sorenmo, K. U., Worley, D. R., & Goldschmidt, M.H. (2013) Tumors of the mammary gland, In: Saunders, D.V. (ed.), Withrow & MacEwen’s small animal clinical oncology (pp. 538-556). Philadelphia, PA: Saunders Company.
  20. Srikanth N, R., Kumar, V. G., Kumar, K. A., & Hs, R. (2021). Changes in serum biochemistry and acute phase proteins in canine mammary tumor affected dogs. The Pharma Innovation Journal, 10(6), 24-25.
  21. Stockhaus, C., Kohn, B., Rudolph R., Brunnberg, L., & Giger, U., (1999). Correlation of Haemostatic Abnormalities with Tumour Stage and Characteristics in Dogs with Mammary Carcinoma. The Journal of Small Animal Practice, 40(7), 326-331.
  22. Taucher S., Salat A., Gnant M., Kwasny W., Mlineritsch B., Menzel R.C., Schmid M., Smola M.G., Stierer M., Tausch C., Galid A., Steger G. & Jakesz R. 2003. Impact of Pretreatment Thrombocytosis on Survival in Primary Breast Cancer. Thrombosis and Haemostasis, 89(6), 1098-1106.
  23. Uribe-Querol, E., Romero-Romero, L., Govezensky, T., & Rosales, C., (2023). Neutrophil to lymphocyte ratio and principal component analysis offer prognostic advantage for dogs with mammary tumors. Frontiers in Veterinary Science, 10, 1187271